Showing 2931-2940 of 5646 results for "".
- Astellas Announces New Data Demonstrating Long-Term Efficacy of Izervay in Slowing GA Progressionhttps://modernod.com/news/astellas-announces-new-data-demonstrating-long-term-efficacy-of-izervay-in-slowing-ga-progression/2484199/Astellas Pharma announced the first results from the open-label extension (OLE) trial of the phase 3 GATHER2 study, which showed that monthly treatment with Izervay (avacincaptad pegol intravitreal solution) continued to slow disease progression in patie
- Formycon Expands Global Reach of Eylea Biosimilar FYB203 with Licensing Deals in Australia and Latin Americahttps://modernod.com/news/formycon-expands-global-reach-of-eylea-biosimilar-fyb203-with-licensing-deals-in-australia-and-latin-america/2484186/Formycon AG announced that its licensing partner Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea¹ biosimilar FYB203 (aflibercept), has signed two new exclusive agreements to broaden the product’s internat
- SpyGlass Pharma Announces Promising 24-Month Interim Results from First-in-Human Trial of BIM-IOL Systemhttps://modernod.com/news/spyglass-pharma-announces-promising-24-month-interim-results-from-first-in-human-trial-of-bim-iol-system/2484179/SpyGlass Pharma announced interim 24-month data from its first-in-human clinical trial evaluating the Bimatoprost Drug Pad-IOL System (BIM-IOL System). This technology integrates proprietary non-bioerodible drug pads with SpyGlass Pharma’s IOL, designed
- Visionix USA to Debut VX 40 Couture Auto Lensmeter at Vision Expo Westhttps://modernod.com/news/visionix-usa-to-debut-vx-40-couture-auto-lensmeter-at-vision-expo-west/2484141/Visionix USA will unveil its latest innovation—the VX 40 Couture—at Vision Expo West, September 18–21 at the Venetian Expo Center in Las Vegas. According to Visionix, the VX 40 Couture is a next-
- Nanoscope Secures EMA Orphan Designations and FDA RMAT Status for Retinal Gene Therapy MCO-010https://modernod.com/news/nanoscope-secures-ema-orphan-designations-and-fda-rmat-status-for-retinal-gene-therapy-mco-010/2484130/Nanoscope Therapeutics announced regulatory milestones in both Europe and the United States for its lead gene therapy candidate, MCO-010 (sonpiretigene isteparvovec). The European Medicines Agency (EMA) has granted Orphan D
- Myra Vision Secures FDA Approval to Initiate US-Based IDE Study in Glaucomahttps://modernod.com/news/myra-vision-secures-fda-approval-to-initiate-us-based-ide-study-in-glaucoma/2482933/Myra Vision announced today that the FDA has issued a conditional approval letter for its investigational device exemption (IDE) application, allowing the company to initiate the ADAPT study. The prospective, nonr
- Ocular Therapeutix Secures FDA Special Protocol Assessment for NPDR Trial of Axpaxlihttps://modernod.com/news/ocular-therapeutix-secures-fda-special-protocol-assessment-for-npdr-trial-of-axpaxli/2482930/Ocular Therapeutix has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the registrational trial design of Axpaxli (OTX-TKI) for the treatment of nonproliferative diabetic retinopathy (NPDR).
- OKYO Pharma Secures Funding to Advance Urcosimod for Neuropathic Corneal Painhttps://modernod.com/news/okyo-pharma-secures-funding-to-advance-urcosimod-for-neuropathic-corneal-pain/2482926/OKYO Pharma announced it has received $1.9 million in non-dilutive funding to accelerate the clinical development of urcosimod, the company’s lead candidate for treating Neuropathic Corneal Pain (NCP) “Neur
- PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHThttps://modernod.com/news/polyactiva-enrolls-first-patient-in-us-phase-2b-clinical-trial-of-its-ocular-micro-implant-for-glaucoma-and-ocular-hypertension/2482925/PolyActiva announced the enrollment of the first US patient in its phase 2b clinical trial evaluating PA5108, a novel intracameral, biodegradable micro implant designed to provide sustained IOP reduction in patients with primary open-angle glaucoma (POAG)
- EyePoint Completes Enrollment of Phase 3 Trials for Duravyu in Wet AMDhttps://modernod.com/news/eyepoint-completes-enrollment-of-phase-3-trials-for-duravyu-in-wet-amd/2482907/EyePoint Pharmaceuticals has completed enrollment of its phase 3 pivotal program with the full enrollment of the LUCIA trial, the second of two identical ongoing pivotal noninferiority trials evaluating Duravyu for the treatment of wet age-related macular degeneration (AMD). The first p